Elder Pharma to enter regulated markets of European Union
With approval from COS and EQDM, Elder Pharma is set to enter regulated markets of European Union.
Mumbai, November 25, 2012: After securing the receipt of Certificate of Suitability (COS) from European Directorate for the Quality of Medicines and Healthcare (EDQM) for Diosmin API, Elder Pharma is all set to enter the regulated markets of the European Union (EU).
The company believes that the recognition of EQDM will immensely help in entering the regulated markets of EU and the COS approval will also help the company to expand its global market share.
It is worth noting here that Diosmin, a semi-synthetic drug, is an oral phlebotropic drug used in the treatment of venous system related diseases. The company has already received approval from the Ministry of Health-Japan for its Diosmin API plant at Patanganga in Maharashtra.
Indian companies have emerged as the preferred supplier for APIs across the world and now rank amongst the top three API producers in the world. It is estimated that 40 per cent of the world's API requirement is met by India.